OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS

Bayan K., ÇELEN M. K. , Dal T., AYAZ C., TEKİN R., Akdemir I., ...Daha Fazla

ACTA MEDICA MEDITERRANEA, cilt.34, sa.1, ss.71-75, 2018 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 34 Konu: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.19193/0393-6384_2018_1_12
  • Dergi Adı: ACTA MEDICA MEDITERRANEA
  • Sayfa Sayıları: ss.71-75

Özet

Introduction: Achieving sustained virologic response (SVR) is critical in HCV patients. In current study, we aimed to investigate the efficacy and safety of DAA (OBV/PTV/r + DSV +/- RBV) treatment regimen in patients with HCV.